Dr. Jayaram Chigurupati
Jayaram Chigurupati (Jay)
has a Ph.D. in genetics (1988) and an MBA from Cornell (1994). His last assignment was as Executive Vice President of Dr. Reddy’s Laboratories Limited. In that position, he started and managed its biotechnology and oncology strategic business units as well as managed marketing in emerging markets around the world including Russia, China and Brazil. All these SBUs have grown to become critical assets for Dr. Reddy’s.

A few of his notable achievements are:

Started several Bio Pharma companies including Dr.Reddy's biologics division. Responsible for launching E-Coli based Biosimilar in India - Filgrastim.

Headed team that developed and launched several Biosimilar and monoclonal antibody bio pharmaceuticals. Executed, several manufacturing facilities for producing oncology and biologics injectables.

US FDA approval for general injectable and manufacturing facility in India in 2011.

Responsible for source plasma BLA approval in 2015 in USA.

As head of Dr.Redyy's Emerging markets marketing responsible for marketing pharmaceutical including oncology injectables in 35 countries including India, Russia, China and Brazil.

Dr. Denis Broun
Dr. Denis Broun
obtained his Masters in Biomathematics (1977) and Medical Doctor Degree (1981) from the University of Paris. He then specialized in Tropical Medicine from Institute Leon Mob, University of Paris, 1982. He is also Diploma cum magna laude of the Paris Institute of Political Sciences, 1984.Denis Broun is presently the UNAIDS Regional Director for Europe and Central Asia. He earlier assignment was UNAIDS Country Coordinator, India. He has an extensive background in donor coordination and more than 15 years of experience in public health. His previous positions as Program Manager and then as Director of Department of Resource Mobilization at WHO (1998 to 2000), Chief of Health and Special Advisor to the Executive Director at UNICEF (1996 and 1998), Health Financing Specialist and Senior Health Specialist at the World Bank (1991 and 1996) have involved inter-agency communication and coordination in fields ranging from infectious diseases to child health. Dr. Broun has also managed all aspects of health policy planning and development. He has extensive experience in project design and management. Dr. Broun has particular expertise in public/private partnerships and private sector collaboration, donor coordination, and has extensive international experience. He joined the Board of Hemarus Therapeutics Limited from December, 2013.

Mr. Dipak Chattaraj
Mr. Dipak Chattaraj
retired as the Chairman of Ranbaxy Inc., USA and President (Corporate Development & Strategy), Ranbaxy Laboratories Ltd on December 31, 2010. He was instrumental in setting up the trend setting Ranbaxy’s US and Canada operations from their very inception as the President and CEO. In 2005, he relinquished the day to day responsibilities of these operations to take up the Corporate Development role for Ranbaxy Laboratories to drive the Company to the high growth verticals of biotechnology, vaccines and oncology etc. following the M&A and licensing routes. In this role he was also responsible for corporate strategy and planning.

Prior to joining Ranbaxy in 1991, Mr. Dipak was with the State Trading Corporation of India Ltd. having joined them as a Management Trainee in 1972. With STC, he played a pioneering role in organizing the then nascent exports of pharmaceuticals exports from India besides being integrally involved in the imports of pharmaceutical substances and intermediates for the entire Indian industry.

Dipak holds a masters degree in economics. He has travelled extensively through all the continents in pursuit of global business opportunities not only in pharmaceuticals but in other areas, both commodities and manufactured products.

Mr. Dipak joined the Board of Hemarus Therapeutics Limited from February, 2013.

Professor Vithala R. Rao
Professor Vithala R. Rao
joined the Board of Directors of Cypress Trust Company in 2017. He is the Deane Malott Professor of Management and Professor of Marketing and Quantitative Methods, Johnson Graduate School of Management, Cornell University, Ithaca, New York. Professor Rao holds Masters Degrees in Mathematical Statistics from the University of Bombay and in Sociology from the University of Michigan and a Ph.D. in Applied Economics/Marketing from the Wharton School of the University of Pennsylvania.

He has been honored with the 2000-01 Faculty Research Award of the Johnson School of Management at Cornell University, the 2005 Robert D. Buzzell Award for the Best Paper by the Marketing Science Institute and the 2008 Charles Coolidge Parlin Marketing Research Award presented by the American Marketing Association and the American Marketing Association Foundation. Professor Rao was selected as the ISMS Fellow in 2012 in recognition of his significant contributions in research, education and service to the Society of Marketing Science’s efforts to improve the understanding and practice of marketing. More recently in 2016, the American Marketing Association awarded the distinction of “AMA Fellow” for his significant contributions to the research, theory and practice of marketing.

He serves on the editorial boards of Journal of Marketing, Customer Needs and Solutions, Journal of Marketing Research, Marketing Science and Journal of Business-to-Business Marketing. He is also an ad hoc reviewer for several journals including Management Science. Professor Rao was the past Chair of the Marketing Strategy Committee of INFORMS and a Board Member of Zenotech Laboratories from 2005 to 2008. He has taught at several Schools including the Fuqua School of Business of Duke University, Columbia Graduate School of Business and the Indian School of Business, Hyderabad, India.

Professor Vithala R. Rao joined the Board of Hemarus Therapeutics Limited from February 2016.

Dr. Uma Devi Komath
Dr. Uma Devi Komath
has a Ph.D in Protein chemistry (CCMB), DBT Post Doc fellow and CSIR Research Associate with a combined post doctoral experience of 4 years and twenty years of experience in the biotechnology industry.

She worked as Vice President (Research and Technical Services) at Zenotech Laboratories Ltd and Successfully oversaw three recombinant therapeutic proteins through development, production, regulatory approvals and commercial launch (G-CSF, GM-CSF, IL-2; brand names Nugraf, Macrogen and Recil respectively) and two biosimilar monoclonal antibodies (Rituximab and Etanercept) till clinical trials stage.

She also worked as Senior Manager, Biotech R&D at Dr. Reddy’s Laboratories Ltd. And conducted and trained a team for protein purification activities forvarious biosimilar therapeutic proteins like Filgrastim (G-CSF), GH, EPO, GM-CSF and TNF alpha and diagnostic proteins like HIV p24 and gp41 and initiated proteomic profiling of cancer tissues at Zenovus (a subsidiary of DRL). She was instrumental in launching the first biosimilar filgrastim in India.

Dr. Uma Devi Komath has joined the Board of Hemarus Therapeutics Limited in September, 2014.

Copyrights © Hemarus. All Rights Reserved. Home R & D Manufacturing Products Board Careers Plasma Collection Contact Us